Cimetidine in duodenal ulcer. Controlled trial

Current treatments for duodenal ulcers include acid suppression, but the effectiveness of cimetidine at different doses remains unclear. Prior research has shown that acid-reducing drugs may promote healing, but uncertainty remains about optimal dosing and long-term safety. This gap motivated a controlled trial to evaluate cimetidine's impact on ulcer healing. No prior work had resolved how dosage affects outcomes or potential side effects. Established knowledge includes that H2 blockers like cimetidine reduce gastric acid secretion. However, it was already known that higher doses may increase the risk of liver or kidney effects. This paper's contribution is to compare healing rates and safety at two cimetidine doses. The study addresses whether a higher dose improves healing without unacceptable toxicity.

This study aimed to assess cimetidine's effectiveness in healing duodenal ulcers at two doses: 1.6 g and 0.8 g daily. The specific problem was to determine if a higher dose improves healing rates without increasing toxicity. Motivation came from the need to optimize treatment protocols for ulcers. The study also sought to evaluate safety markers like liver enzymes and kidney function. By comparing placebo and active treatment groups, the researchers aimed to isolate cimetidine's effects. The double-blind design ensured unbiased assessment of healing outcomes. The open pilot trial provided additional data on dose equivalence. The study's goal was to inform clinical guidelines on cimetidine use.

The study used a double-blind controlled design with endoscopic follow-up in 24 patients after two and six weeks of treatment. Patients were assigned to receive either 1.6 g of cimetidine or a placebo. Healing was assessed via repeat endoscopy at six weeks. A separate open pilot trial compared 0.8 g and 1.6 g doses in 23 patients. The primary outcome was ulcer healing at six weeks. Secondary outcomes included changes in liver enzymes and serum creatinine. Bone marrow toxicity was monitored through clinical observation. The study combined data from both trials to assess overall healing rates and safety.

At six weeks, 9 out of 11 patients on cimetidine had healed ulcers compared to 3 out of 12 on placebo (P < 0.025). The open trial showed no difference in healing between 0.8 g and 1.6 g doses. Overall, 21 out of 32 patients on cimetidine had healed ulcers. No patients showed bone marrow toxicity. A significant rise in mean SGOT, SGPT, and serum creatinine occurred in 13 patients on 1.6 g but not in those on 0.8 g. The 1.6 g dose was more effective than placebo but carried a higher risk of liver and kidney effects. The 0.8 g dose showed similar healing rates without increased toxicity. These findings suggest a trade-off between efficacy and safety at higher doses.

The authors found that cimetidine at 1.6 g daily was more effective than placebo in healing duodenal ulcers. However, this dose increased liver and kidney markers. The 0.8 g dose showed similar healing without increased toxicity. These findings suggest that higher doses may not be necessary for optimal healing. The study supports using cimetidine at 0.8 g for safety and efficacy. No patients experienced bone marrow toxicity, which is an important safety consideration. The results indicate that dose optimization is crucial for balancing healing and side effects. The authors propose that future research should explore long-term effects and alternative dosing strategies. The study provides evidence that lower doses may be as effective as higher ones with fewer risks.